BLU-554,
1707289-21-1,
Fisogatinib,
BLU554,
N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide,
Fisogatinib [INN],
fisogatinib (proposed INN),
UNII-5Q7R99CKV2,
5Q7R99CKV2,
BLU 554 [WHO-DD],
SCHEMBL16668287,
GTPL10220,
EX-A841,
MGZKYOAQVGSSGC-DLBZAZTESA-N,
BLU-554 (BLU554),
CS3008,
MFCD30496704,
s8503,
AKOS030632994,
ACN-037513,
CS-5986,
AC-29871,
HY-100492,
2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-,
N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide,
N-[(3S,4S)-3-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl]amino]tetrahydro-2H-pyran-4-yl]-2-propenamide,
CS-3008,